Compare CSV & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSV | AGMB |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | 62 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.0M | 562.4M |
| IPO Year | 1996 | N/A |
| Metric | CSV | AGMB |
|---|---|---|
| Price | $38.16 | $10.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $59.00 | $32.00 |
| AVG Volume (30 Days) | ★ 125.4K | 82.0K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 54.76 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $417,440,000.00 | N/A |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $3.87 | $17.86 |
| P/E Ratio | $45.06 | ★ N/A |
| Revenue Growth | ★ 3.28 | N/A |
| 52 Week Low | $37.11 | $8.75 |
| 52 Week High | $52.10 | $17.45 |
| Indicator | CSV | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 52.12 |
| Support Level | $37.11 | $9.54 |
| Resistance Level | $44.93 | $12.53 |
| Average True Range (ATR) | 1.40 | 1.10 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 22.44 | 52.47 |
Carriage Services Inc is a provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: The Funeral Home Operations segment offers burial, cremation, and consultation services; removes and prepares remains; sells caskets, urns, and related funeral merchandise. The company enables the use of funeral home facilities for visitation, remembrance, and transportation services. The Cemetery Operations segment provides services, such as mausoleum spaces and niches, private estates, lawn crypt gardens, traditional single burial gravesites, and burial vaults. The majority of revenue is derived from The Funeral Home Operations segment.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.